Dr. Eskelund Discusses TP53 Mutated Mantle Cell Lymphoma

Video

Christian Winther Eskelund, MD, Copenhagen University Hospital, Rigshospitalet, discusses TP53-mutated mantle cell lymphoma (MCL).

Christian Winther Eskelund, MD, Copenhagen University Hospital, Rigshospitalet, discusses TP53-mutated mantle cell lymphoma (MCL).

TP53 has been associated with poor outcomes in many different cohorts of MCL, says Eskelund.

Eskelund suggests that TP53 status should be measured upfront in patients who are diagnosed with MCL. As clinical trials become available, treating physicians should highly consider entering their patients onto them.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,